BOULDER - Fresh Tracks Therapeutics, Inc. , a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the.
By Sabela Ojea Fresh Tracks Therapeutics said Friday that it is selling the rights to future sales of the drug sofpironium bromide to Botanix SB for $8.3.
Fresh Tracks Announces $8 25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Fresh Tracks Therapeutics (FRTX) Announces $8 25M Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.